Overview A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors Status: Unknown status Trial end date: 2020-12-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the safety of SHR-1702 monotherapy or in combination with Camrelizumab among advanced solid tumor subjects. Phase: Phase 1 Details Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.